research Efficacy of Baricitinib in Patients With Various Degrees of Alopecia Areata Severity: Results From Brave-AA1 and Brave-AA2
Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
Search
for
Sort by
Research
450-480 / 712 results 
research Efficacy and Safety of Baricitinib in Adult Patients With Severe Alopecia Areata With or Without an Atopic Background From Two Randomized, Placebo-Controlled, Phase 3 Trials
Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
research Efficacy of Albumin-Bound Paclitaxel Combined with Nedaplatin in Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma: A Single-Center Retrospective Observational Study
The combination therapy is effective and well-tolerated for treating esophageal cancer.
research Baricitinib Results in Eyebrow and Eyelash Growth in Patients With Alopecia Areata Who Do Not Achieve 20% or Less Scalp Hair Loss
Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
research Current Best Evidence in Pigmentary Dermatology
Several treatments are effective for pigmentary disorders like vitiligo and melasma.
research Baricitinib Maintains Regrowth of Hair, Eyebrows, and Eyelashes Over 3 Years
Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.
research Methylation of SRD5A2 in the Blood as a Novel Biomarker to Predict Sensitivity to 5-ARI Treatment
SRD5A2 methylation in blood can predict how well someone will respond to finasteride treatment.
research Treatment Preferences of Adults and Adolescents with Alopecia Areata: A Discrete Choice Experiment
Adults and adolescents with severe alopecia areata are willing to take significant health risks for a better chance of hair regrowth.
research Improvement in Health-Related Quality of Life and Symptoms of Anxiety and Depression in Patients with Alopecia Areata Randomized to Baricitinib or Placebo: Results from Two International Randomized Controlled Trials
Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
research Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
research Clinician and Patient Evaluation of Improvement for Eyebrow and Eyelashes Hair Loss During Baricitinib Phase 3 Trials BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
research JAK Inhibitors in Dermatology: The Promise of a New Drug Class
JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
research Blinded, Randomized, Quantitative Grading Comparison of Minimally Invasive, Fractional Radiofrequency and Surgical Face-Lift to Treat Skin Laxity
Surgical face-lifts are more effective, but fractional radiofrequency is a good, less invasive alternative for treating skin laxity.
research Hair Regrowth in Alopecia Areata Patients Following Stem Cell Educator Therapy
Stem Cell Educator therapy helps regrow hair and improve life quality in alopecia areata patients.
research Clobetasol Propionate, 0.05%, vs Hydrocortisone, 1%, for Alopecia Areata in Children
Clobetasol propionate, 0.05%, is more effective and safe for treating childhood alopecia areata than hydrocortisone, 1%.
research A Six-Month, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of a Nutraceutical Supplement for Promoting Hair Growth in Women With Self-Perceived Thinning Hair
Nutrafol® Women's Capsules safely and effectively promote hair growth in women with thinning hair.
research Anti-Acne Drugs in Phase 1 and 2 Clinical Trials
New anti-acne medications are being tested to offer alternatives to current treatments.
research Platelet-Rich Plasma for the Treatment of Erectile Dysfunction: A Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial
PRP is safe but not more effective than a placebo for treating mild to moderate erectile dysfunction.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research Treatment of Keratosis Pilaris With 810-nm Diode Laser
The 810-nm diode laser improves skin texture in keratosis pilaris but not redness.
research Dupilumab Therapy for Alopecia Areata in Pediatric Patients with Concomitant Atopic Dermatitis
Dupilumab may help children with alopecia areata and atopic dermatitis regrow hair.
research Incidence of Androgenic Dermatologic Side Effects Following Placement of a Levonorgestrel Intrauterine Device for Menorrhagia: A Survey-Based Study
The levonorgestrel intrauterine device for heavy periods may cause acne, hair loss, and excess hair growth.
research Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer
Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.
research FASCE: The Benefit of Spironolactone for Treating Acne in Women - Study Protocol for a Randomized Double-Blind Trial
The trial aims to test if spironolactone is an effective acne treatment for women without the side effects of current treatments.
research A Synbiotic Preparation (SIM01) for Post-Acute Covid-19 Syndrome in Hong Kong (Recovery): A Randomised, Double-Blind, Placebo-Controlled Trial
SIM01 significantly reduced post-COVID symptoms and is safe.
research Safety and Efficacy of ALRV5XR in Women with Androgenetic Alopecia or Telogen Effluvium: A Randomised, Double-Blinded, Placebo-Controlled Clinical Trial
ALRV5XR significantly improves hair density in women with hair loss and is well-tolerated.
research Proxalutamide Reduces Hospitalization Rate in Mild-to-Moderate COVID-19 Female Patients: A Randomized Double-Blinded Placebo-Controlled Trial
Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.
research Biologics in the Management of Childhood Atopic Dermatitis
Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.
research CFTR Potentiator Ivacaftor Protects Against Noise-Induced Hair Cell Loss by Increasing Nrf2 and Reducing Oxidative Stress
Ivacaftor can protect against noise-induced hearing loss by reducing oxidative stress.
research Protective Trend of Anti-Androgen Therapy During the COVID-19 Pandemic: A Meta-Analysis
Anti-androgen therapy might help protect against COVID-19 infection and reduce death risk.